

Reviewers for 1992

We wish to acknowledge the important assistance we have received from many scientists, who, along with the Editorial Board, have evaluated manuscripts submitted for publication during 1992. All outside reviewers are listed in the December issue of *Psychiatry Research* (Volume 44, Number 3, 1992).

Author Index for 1992

- Abbruzzese, M. 45:115
Adams, R.N. 45:203
Agartz, I. 45:139
Aigner, T.G. 45:153
Alliger, R. 45:33
Amass, L. 45:15
Anderer, P. 45:79
Andreasen, N.C. 45:33
Arndt, S. 45:33
Ashtari, M. 45:1
Baldwin, R.M. 45:67
Barbanoj, M.J. 45:79
Berman, K.F. 45:187
Bird, E.D. 45:203
Bjurling, P. 45:215
Bogerts, B. 45:1
Bossuyt, A. 45:227
Bossuyt-Piron, C. 45:227
Charney, D.S. 45:67
Cohen, G. 45:33
Cohen, R.M. 45:153
Colombo, C. 45:115
Cooper, J.E. 45:123
Coppola, R. 45:105
Coppola, R. 45:187
Costa, D.C. 45:143
D'haenen, H. 45:215
Degreef, G. 45:1
Dey, H.M. 45:67
Doudet, D.J. 45:153
Ebert, D. 45:239
Ehrhardt, J. 45:33
Ell, P.G. 45:143
Fairbanks, L.A. 45:177
Falkai, P. 45:1
Feistel, H. 45:239
Ford, R.A. 45:209
George, M.S. 45:143
Germine, M. 45:67
Gijsemans, M. 45:227
Gleason, R.P. 45:25
Goddard, A.W. 45:67
Greve, B. 45:1
Guze, B.H. 45:169
Guze, B.H. 45:177
Harrison, G. 45:123
Hartvig, P. 45:215
Heninger, G.R. 45:67
Hoffer, P.B. 45:67
Innis, R.B. 45:67
Inubushi, T. 45:53
Jones, D.W. 45:187
Karson, C.N. 45:95
Kaschka, W. 45:239
Kato, T. 45:53
Kaufman, L. 45:227
Kihlberg, T. 45:215
Komoroski, R.A. 45:95
Kuan, J. 45:33
Långström, B. 45:215
Lantos, G. 45:1
Lencz, T. 45:123
Lewis, S.W. 45:209
Lieberman, J. 45:1
Livian, S. 45:115
Locatelli, M. 45:115
Lundqvist, H. 45:215
Mandelkern, M.A. 45:177
Marenco, S. 45:187
Marions, O. 45:139
McLellan, C.A. 45:153
Medley, I. 45:123
Mendelson, J.H. 45:15
Mertens, J. 45:227
Min, C.A. 45:177
Mohanakrishnan, P. 45:95
Nardin, R. 45:15
Newman, F. 45:105
Newton, J.E.O. 45:95
Oke, A.F. 45:203
Pawluczyk, S. 45:25
Pollock, V.E. 45:25
Putz, C. 45:203
Raine, A. 45:123
Reibring, L. 45:215
Reveley, A. 45:209
Reynolds, G.P. 45:123
Reynolds, L.M. 45:123

- Ring, H.A. 45:143
Robertson, M.M. 45:143
Ronchi, P. 45:115
Sääf, J. 45:139
Saletu, B. 45:79
Scarone, S. 45:115
Schneider, L.S. 45:25
Scotti, G. 45:115
Seibyl, J.P. 45:67
Semlitsch, H.V. 45:79
Sheard, C. 45:123
Small, G.W. 45:177
Smeraldi, E. 45:115
Smith, E.O. 45:67
Sprigg, J. 45:95
Stein, M.B. 45:105
Stern, C.E. 45:177
Syed, G.M.S. 45:209
Szuba, M.P. 45:169
Takahashi, S. 45:53
Tedroff, J. 45:215
Teoh, S.K. 45:15
Toone, B.K. 45:209
Trettau, J.R. 45:105
Trimble, M.R. 45:143
Uhde, T.W. 45:105
Wahlund, L.-O. 45:139
Weinberger, D.R. 45:187
Wetterberg, L. 45:139
Woods, B.T. 45:15
Woods, S.W. 45:67
Yuh, W.T.C. 45:33
Zemansky, M.F. 45:25
Zoghbi, S.S. 45:67

Subject Index for 1992

Affective disorder

- age, leukoencephalopathy, 45:159
- age, MRI, 45:159
- bipolar subtype, lithium-7 brain concentration, 45:53
- bipolar subtype, MRI spectroscopy, 45:53
- ketanserin, serotonin₂ receptor, 45:227
- ketanserin, SPECT, 45:227
- leukoencephalopathy, age, 45:159
- leukoencephalopathy, MRI, 45:159
- lithium-7 brain concentration, bipolar subtype, 45:53
- lithium-7 brain concentration, MRI spectroscopy, 45:53
- MRI, age, 45:159
- MRI, leukoencephalopathy, 45:159
- MRI spectroscopy, bipolar subtype, 45:53
- MRI spectroscopy, lithium-7 brain concentration, 45:53
- serotonin₂ receptor, ketanserin, 45:227
- serotonin₂ receptor, SPECT, 45:227
- SPECT, ketanserin, 45:227
- SPECT, serotonin₂ receptor, 45:227
- Age**
- affective disorder, leukoencephalopathy, 45:159
- affective disorder, MRI, 45:159
- leukoencephalopathy, affective disorder, 45:159
- leukoencephalopathy, MRI, 45:159
- MRI, affective disorder, 45:159
- MRI, leukoencephalopathy, 45:159
- Alcoholism**
- electroencephalography, topographic mapping, 45:25
- topographic mapping, electroencephalography, 45:25
- Benzodiazepines**
- iomazenil, normal controls, 45:67
- iomazenil, occipital lobes, 45:67
- iomazenil, SPECT, 45:67
- normal controls, iomazenil, 45:67
- normal controls, occipital lobes, 45:67
- normal controls, SPECT, 45:67
- occipital lobes, iomazenil, 45:67
- occipital lobes, normal controls, 45:67
- occipital lobes, SPECT, 45:67
- SPECT, iomazenil, 45:67
- SPECT, normal controls, 45:67
- SPECT, occipital lobes, 45:67
- Blood flow**
- catatonic syndrome, temporal lobe, 45:239
- schizophrenia, catatonic syndrome, 45:239

Blood flow continued

- schizophrenia, SPECT, 45:239
- schizophrenia, temporal lobe, 45:239
- SPECT, catatonic syndrome, 45:239
- SPECT, schizophrenia, 45:239
- SPECT, temporal lobe, 45:239
- temporal lobe, catatonic syndrome, 45:239
- temporal lobe, schizophrenia, 45:239
- temporal lobe, SPECT, 45:239
- Caffeine**
- electroencephalography, panic disorder, 45:105
- panic disorder, electroencephalography, 45:105
- panic disorder, topographic mapping, 45:105
- topographic mapping, panic disorder, 45:105
- Caudate nucleus**
- MRI, obsessive-compulsive disorder, 45:115
- obsessive-compulsive disorder, MRI, 45:115
- Cavum septum pellucidum**
- MRI, schizophrenia, 45:1
- post-mortem studies, schizophrenia, 45:1
- schizophrenia, MRI, 45:1
- schizophrenia, post-mortem studies, 45:1
- Cerebrospinal fluid**
- image processing, MRI, 45:33
- image processing, segmentation methodology, 45:33
- MRI, image processing, 45:33
- MRI, segmentation methodology, 45:33
- segmentation methodology, image processing, 45:33
- segmentation methodology, MRI, 45:33
- Cocaine**
- heroin, MRI, 45:15
- MRI, heroin, 45:15
- MRI, substance abuse, 45:15
- substance abuse, MRI, 45:15
- Computed tomography**
- frontal lobe, schizophrenia, 45:209
- frontal lobe, SPECT, 45:209
- frontal lobe, ventricular size, 45:209
- schizophrenia, frontal lobe, 45:209
- schizophrenia, SPECT, 45:209
- schizophrenia, ventricular size, 45:209
- SPECT, frontal lobe, 45:209
- SPECT, schizophrenia, 45:209
- SPECT, ventricular size, 45:209
- ventricular size, frontal lobe, 45:209
- ventricular size, schizophrenia, 45:209
- ventricular size, SPECT, 45:209
- DOPA-F¹⁸**
- MPTP, PET, 45:153
- MPTP, primates, 45:153

DOPA-F¹⁸ continued

PET, MPTP, 45:153
 PET, primates, 45:153
 primates, MPTP, 45:153
 primates, PET, 45:153

Dopamine

Huntington's disease, neuroleptics, 45:203
 Huntington's disease, post-mortem study, 45:203
 Huntington's disease, schizophrenia, 45:203
 Huntington's disease, thalamus, 45:203
 neuroleptics, Huntington's disease, 45:203
 neuroleptics, post-mortem study, 45:203
 neuroleptics, schizophrenia, 45:203
 neuroleptics, thalamus, 45:203
 post-mortem study, Huntington's disease, 45:203
 post-mortem study, neuroleptics, 45:203
 post-mortem study, schizophrenia, 45:203
 post-mortem study, thalamus, 45:203
 schizophrenia, Huntington's disease, 45:203
 schizophrenia, neuroleptics, 45:203
 schizophrenia, post-mortem study, 45:203
 schizophrenia, thalamus, 45:203
 thalamus, Huntington's disease, 45:203
 thalamus, neuroleptics, 45:203
 thalamus, post-mortem study, 45:203
 thalamus, schizophrenia, 45:203

Electroencephalography

alcoholism, topographic mapping, 45:25
 artifact elimination, topographic mapping, 45:79
 caffeine, panic disorder, 45:105
 caffeine, topographic mapping, 45:105
 panic disorder, caffeine, 45:105
 panic disorder, topographic mapping, 45:105
 topographic mapping, alcoholism, 45:25
 topographic mapping, artifact elimination, 45:79
 topographic mapping, caffeine, 45:105
 topographic mapping, panic disorder, 45:105

Fluoxetine

MR spectroscopy, neuroleptics, 45:95
 MR spectroscopy, schizophrenia, 45:95
 MR spectroscopy, trifluoperazine, 45:95
 neuroleptics, MR spectroscopy, 45:95
 neuroleptics, schizophrenia, 45:95
 schizophrenia, MR spectroscopy, 45:95
 schizophrenia, neuroleptics, 45:95
 schizophrenia, trifluoperazine, 45:95
 trifluoperazine, MR spectroscopy, 45:95
 trifluoperazine, schizophrenia, 45:95

Frontal lobes

computed tomography, schizophrenia, 45:209

Frontal lobes continued

computed tomography, SPECT, 45:209
 computed tomography, ventricular size, 45:209
 hydroxytryptophan-C¹¹, PCPA, 45:215
 hydroxytryptophan-C¹¹, PET, 45:215
 MRI, neuropsychological tests, 45:123
 MRI, schizophrenia, 45:123
 MRI, Wisconsin Card Sort Test, 45:123
 neuropsychological tests, MRI, 45:123
 neuropsychological tests, schizophrenia, 45:123
 obsessive-compulsive disorder, SPECT, 45:143
 obsessive-compulsive disorder, Tourette's syndrome, 45:143
 PCPA, hydroxytryptophan-C¹¹, 45:215
 PCPA, PET, 45:215
 PET, hydroxytryptophan-C¹¹, 45:215
 PET, PCPA, 45:215
 schizophrenia, computed tomography, 45:209
 schizophrenia, MRI, 45:123
 schizophrenia, neuropsychological tests, 45:123
 schizophrenia, SPECT, 45:209
 schizophrenia, ventricular size, 45:209
 schizophrenia, Wisconsin Card Sort Test, 45:123
 SPECT, computed tomography, 45:209
 SPECT, obsessive-compulsive disorder, 45:143
 SPECT, schizophrenia, 45:209
 SPECT, Tourette's syndrome, 45:143
 SPECT, ventricular size, 45:209
 Tourette's syndrome, obsessive-compulsive disorder, 45:143
 Tourette's syndrome, SPECT, 45:143
 ventricular size, computed tomography, 45:209
 ventricular size, schizophrenia, 45:209
 ventricular size, SPECT, 45:209
 Wisconsin Card Sort Test, MRI, 45:123
 Wisconsin Card Sort Test, schizophrenia, 45:123

Heroin
 cocaine, MRI, 45:15
 MRI, cocaine, 45:15
 MRI, substance abuse, 45:15
 substance abuse, MRI, 45:15

Huntington's disease
 dopamine, neuroleptics, 45:203
 dopamine, post-mortem study, 45:203
 dopamine, schizophrenia, 45:203
 dopamine, thalamus, 45:203
 neuroleptics, dopamine, 45:203
 neuroleptics, post-mortem study, 45:203
 neuroleptics, schizophrenia, 45:203
 neuroleptics, thalamus, 45:203

Huntington's disease continued

post-mortem study, dopamine, 45:203
 post-mortem study, neuroleptics, 45:203
 post-mortem study, schizophrenia, 45:203
 post-mortem study, thalamus, 45:203
 schizophrenia, dopamine, 45:203
 schizophrenia, neuroleptics, 45:203
 schizophrenia, post-mortem study, 45:203
 schizophrenia, thalamus, 45:203
 thalamus, dopamine, 45:203
 thalamus, neuroleptics, 45:203
 thalamus, post-mortem study, 45:203
 thalamus, schizophrenia, 45:203

5-Hydroxytryptophan

frontal lobe, PCPA, 45:215
 frontal lobe, PET, 45:215
 PCPA, frontal lobe, 45:215
 PCPA, PET, 45:215
 PET, frontal lobe, 45:215
 PET, PCPA, 45:215

Image processing

cerebrospinal fluid, MRI, 45:33
 cerebrospinal fluid, segmentation methodology, 45:33
 MRI, cerebrospinal fluid, 45:33
 MRI, segmentation methodology, 45:33
 segmentation methodology, cerebrospinal fluid, 45:33
 segmentation methodology, MRI, 45:33

lomazenil

benzodiazepine receptor ligand, normal controls, 45:67
 benzodiazepine receptor ligand, occipital lobes, 45:67
 benzodiazepine receptor ligand, SPECT, 45:67
 normal controls, benzodiazepine receptor ligand, 45:67
 normal controls, occipital lobes, 45:67
 normal controls, SPECT, 45:67
 occipital lobes, benzodiazepine receptor ligand, 45:67
 occipital lobes, normal controls, 45:67
 occipital lobes, SPECT, 45:67
 SPECT, benzodiazepine receptor ligand, 45:67
 SPECT, normal controls, 45:67
 SPECT, occipital lobes, 45:67

Ketanserin

affective disorder, serotonin₂ receptor, 45:227
 affective disorder, SPECT, 45:227
 serotonin₂ receptor, affective disorder, 45:227
 serotonin₂ receptor, SPECT, 45:227
 SPECT, affective disorder, 45:227
 SPECT, serotonin₂ receptor, 45:227

Leukoencephalopathy

affective disorder, age, 45:159
 affective disorder, MRI, 45:159
 age, affective disorder, 45:159
 age, MRI, 45:159
 MRI, affective disorder, 45:159
 MRI, age, 45:159

Lithium

affective disorder, MRI spectroscopy, 45:53
 bipolar subtype, MRI spectroscopy, 45:53
 MRI spectroscopy, affective disorder, 45:53
 MRI spectroscopy, bipolar subtype, 45:53
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)

DOPA-F¹⁸, PET, 45:153
 DOPA-F¹⁸, primates, 45:153
 PET, DOPA-F¹⁸, 45:153
 PET, primates, 45:153
 primates, DOPA-F-18, 45:153
 primates, PET, 45:153

MRI (magnetic resonance imaging)

affective disorder, age, 45:159
 affective disorder, leukoencephalopathy, 45:159
 age, affective disorder, 45:159
 age, leukoencephalopathy, 45:159
 caudate nucleus, obsessive-compulsive disorder, 45:115
 cavum septum pellucidum, post-mortem studies, 45:1
 cavum septum pellucidum, schizophrenia, 45:1
 cerebrospinal fluid, imageprocessing, 45:33
 cerebrospinal fluid, segmentation methodology, 45:33
 cocaine, heroin, 45:15
 frequency of brain pathology, psychiatric patients, 45:139
 frontal lobe, neuropsychological tests, 45:123
 frontal lobe, schizophrenia, 45:123
 frontal lobe, Wisconsin Card Sort Test, 45:123
 heroin, cocaine, 45:15
 image processing, cerebrospinal fluid, 45:33
 image processing, segmentation methodology, 45:33
 leukoencephalopathy, affective disorder, 45:159
 leukoencephalopathy, age, 45:159
 neuropsychological tests, frontal lobe, 45:123
 neuropsychological tests, schizophrenia, 45:123
 obsessive-compulsive disorder, caudate nucleus, 45:115
 post-mortem studies, cavum septum

MRI continued

- pellucidum, 45:1
- post-mortem studies, schizophrenia, 45:1
- psychiatric patients, frequency of brain pathology, 45:139
- schizophrenia, cavum septum pellucidum, 45:1
- schizophrenia, frontal lobe, 45:123
- schizophrenia, neuropsychological tests, 45:123
- schizophrenia, post-mortem studies, 45:1
- schizophrenia, Wisconsin Card Sort Test, 45:123
- segmentation methodology, cerebrospinal fluid, 45:33
- segmentation methodology, image processing, 45:33
- substance abuse, 45:15
- Wisconsin Card Sort Test, frontal lobe, 45:123
- Wisconsin Card Sort Test, schizophrenia, 45:123

MR (magnetic resonance) spectroscopy

- affective disorder, lithium-7 brain concentration, 45:53
- bipolar subtype, lithium-7 brain concentration, 45:53
- fluoxetine, neuroleptics, 45:95
- fluoxetine, schizophrenia, 45:95
- fluoxetine, trifluoperazine, 45:95
- lithium-7 brain concentration, affective disorder, 45:53
- lithium-7 brain concentration, bipolar subtype, 45:53
- neuroleptics, fluoxetine, 45:95
- neuroleptics, schizophrenia, 45:95
- schizophrenia, fluoxetine, 45:95
- schizophrenia, neuroleptics, 45:95
- schizophrenia, trifluoperazine, 45:95
- trifluoperazine, fluoxetine, 45:95
- trifluoperazine, schizophrenia, 45:95

Neuroleptics

- dopamine, Huntington's disease, 45:203
- dopamine, post-mortem study, 45:203
- dopamine, schizophrenia, 45:203
- dopamine, thalamus, 45:203
- fluoxetine, trifluoperazine, 45:95
- Huntington's disease, dopamine, 45:203
- Huntington's disease, post-mortem study, 45:203
- Huntington's disease, schizophrenia, 45:203
- Huntington's disease, thalamus, 45:203
- MR spectroscopy, schizophrenia, 45:95
- MR spectroscopy, trifluoperazine, 45:95
- post-mortem study, dopamine, 45:203
- post-mortem study, Huntington's disease, 45:203

Neuroleptics continued

- post-mortem study, schizophrenia, 45:203
- post-mortem study, thalamus, 45:203
- schizophrenia, dopamine, 45:203
- schizophrenia, Huntington's disease, 45:203
- schizophrenia, MR spectroscopy, 45:95
- schizophrenia, post-mortem study, 45:203
- schizophrenia, thalamus, 45:203
- schizophrenia, trifluoperazine, 45:95
- thalamus, dopamine, 45:203
- thalamus, Huntington's disease, 45:203
- thalamus, post-mortem study, 45:203
- thalamus, schizophrenia, 45:203
- trifluoperazine, fluoxetine, 45:95
- trifluoperazine, MR spectroscopy, 45:95
- trifluoperazine, schizophrenia, 45:95

Neuropsychological tests

- frontal lobe, MRI, 45:123
- frontal lobe, schizophrenia, 45:123
- frontal lobe, Wisconsin Card Sort Test, 45:123
- MRI, frontal lobe, 45:123
- MRI, schizophrenia, 45:123
- MRI, Wisconsin Card Sort Test, 45:123
- schizophrenia, frontal lobe, 45:123
- schizophrenia, MRI, 45:123
- schizophrenia, Wisconsin Card Sort Test, 45:123
- Wisconsin Card Sort Test, frontal lobe, 45:123
- Wisconsin Card Sort Test, MRI, 45:123
- Wisconsin Card Sort Test, schizophrenia, 45:123

Obsessive-compulsive disorder

- caudate nucleus, MRI, 45:115
- frontal lobe, SPECT, 45:143
- frontal lobe, Tourette's syndrome, 45:143
- MRI, caudate nucleus, 45:115
- SPECT, frontal lobe, 45:143
- SPECT, Tourette's syndrome, 45:143
- Tourette's syndrome, frontal lobe, 45:143
- Tourette's syndrome, SPECT, 45:143

Occipital lobe

- benzodiazepine receptor ligand, iomazenil, 45:67
- benzodiazepine receptor ligand, normal controls, 45:67
- benzodiazepine receptor ligand, SPECT, 45:67
- iomazenil, normal controls, 45:67
- iomazenil, SPECT, 45:67
- normal controls, benzodiazepine receptor ligand, 45:67
- normal controls, iomazenil, 45:67
- normal controls, SPECT, 45:67

Occipital lobe continued

SPECT, benzodiazepine receptor ligand, 45:67

SPECT, iomazenil, 45:67

SPECT, normal controls, 45:67

Panic disorder

caffeine, electroencephalography, 45:105

caffeine, topographic mapping, 45:105

electroencephalography, caffeine, 45:105

topographic mapping, caffeine, 45:105

PCPA (para-chlorophenylalanine)

frontal lobe, hydroxytryptophan-C¹¹, 45:215

frontal lobe, PET, 45:215

hydroxytryptophan-C¹¹, frontal lobe, 45:215

hydroxytryptophan-C¹¹, PET, 45:215

PET, frontal lobe, 45:215

PET, hydroxytryptophan-C¹¹, 45:215

PET (positron emission tomography)

DOPA-F¹⁸, MPTP, 45:153

DOPA-F¹⁸, primates, 45:153

frontal lobe, hydroxytryptophan-C¹¹, 45:215

frontal lobe, PCPA, 45:215

hydroxytryptophan-C¹¹, frontal lobe, 45:215

hydroxytryptophan-C¹¹, PCPA, 45:215

MPTP, DOPA-F¹⁸, 45:153

MPTP, primates, 45:153

PCPA, frontal lobe, 45:215

PCPA, hydroxytryptophan-C¹¹, 45:215

primates, DOPA-F¹⁸, 45:153

primates, MPTP, 45:153

region of interest methodology, reliability, 45:177

Primates

DOPA-F¹⁸, MPTP, 45:153

DOPA-F¹⁸, PET, 45:153

MPTP, DOPA-F¹⁸, 45:153

MPTP, PET, 45:153

PET, DOPA-F¹⁸, 45:153

PET, MPTP, 45:153

Schizophrenia

blood flow, catatonic syndrome, 45:239

blood flow, SPECT, 45:239

blood flow, temporal lobe, 45:239

catatonic syndrome, blood flow, 45:239

catatonic syndrome, SPECT, 45:239

catatonic syndrome, temporal lobe, 45:239

cavum septum pellucidum, MRI, 45:1

cavum septum pellucidum, post-mortem

studies, 45:1

computed tomography, frontal lobe, 45:209

computed tomography, SPECT, 45:209

computed tomography, ventricular size, 45:209

dopamine, Huntington's disease, 45:203

dopamine, neuroleptics, 45:203

Schizophrenia continued

dopamine, post-mortem study, 45:203

dopamine, thalamus, 45:203

fluoxetine, MR spectroscopy, 45:95

fluoxetine, neuroleptics, 45:95

fluoxetine, trifluoperazine, 45:95

frontal lobe, computed tomography, 45:209

frontal lobe, MRI, 45:123

frontal lobe, neuropsychological tests, 45:123

frontal lobe, SPECT, 45:209

frontal lobe, ventricular size, 45:209

frontal lobe, Wisconsin Card Sort Test, 45:123

Huntington's disease, dopamine, 45:203

Huntington's disease, neuroleptics, 45:203

Huntington's disease, post-mortem study, 45:203

Huntington's disease, thalamus, 45:203

MR spectroscopy, fluoxetine, 45:95

MR spectroscopy, neuroleptics, 45:95

MR spectroscopy, trifluoperazine, 45:95

MRI, cavum septum pellucidum, 45:1

MRI, frontal lobe, 45:123

MRI, neuropsychological tests, 45:123

MRI, post-mortem studies, 45:1

MRI, Wisconsin Card Sort Test, 45:123

neuroleptics, dopamine, 45:203

neuroleptics, fluoxetine, 45:95

neuroleptics, Huntington's disease, 45:203

neuroleptics, MR spectroscopy, 45:95

neuroleptics, post-mortem study, 45:203

neuroleptics, thalamus, 45:203

neuropsychological tests, frontal lobe, 45:123

neuropsychological tests, MRI, 45:123

post-mortem studies, cavum septum pellucidum, 45:1

post-mortem studies, MRI, 45:1

post-mortem study, dopamine, 45:203

post-mortem study, Huntington's disease, 45:203

post-mortem study, neuroleptics, 45:203

post-mortem study, thalamus, 45:203

SPECT, blood flow, 45:239

SPECT, catatonic syndrome, 45:239

SPECT, computed tomography, 45:209

SPECT, frontal lobe, 45:209

SPECT, temporal lobe, 45:239

SPECT, ventricular size, 45:239

temporal lobe, blood flow, 45:239

temporal lobe, catatonic syndrome, 45:239

temporal lobe, SPECT, 45:239

thalamus, dopamine, 45:203

thalamus, Huntington's disease, 45:203

thalamus, neuroleptics, 45:203

thalamus, post-mortem study, 45:203

Schizophrenia continued

trifluoperazine, fluoxetine, 45:95
trifluoperazine, MR spectroscopy, 45:95
ventricular size, computed tomography, 45:209

ventricular size, frontal lobe, 45:209

ventricular size, SPECT, 45:209

Wisconsin Card Sort Test, frontal lobe, 45:123

Wisconsin Card Sort Test, MRI, 45:123

Segmentation techniques

cerebrospinal fluid, image processing, 45:33

cerebrospinal fluid, MRI, 45:33

image processing, cerebrospinal fluid, 45:33

image processing, MRI, 45:33

MRI, cerebrospinal fluid, 45:33

MRI, image processing, 45:33

Serotonin

affective disorder, ketanserin, 45:227

affective disorder, SPECT, 45:227

ketanserin, affective disorder, 45:227

ketanserin, SPECT, 45:227

SPECT, affective disorder, 45:227

SPECT, ketanserin, 45:227

SPECT (single photon emission computed tomography)

affective disorder, ketanserin, 45:227

affective disorder, serotonin₂ receptor, 45:227

benzodiazepine receptor ligand, iomazenil, 45:67

benzodiazepine receptor ligand, normal controls, 45:67

benzodiazepine receptor ligand, occipital lobes, 45:67

blood flow, xenon-133 vs. xenon-127, 45:187

bloodflow, catatonic syndrome, 45:239

bloodflow, schizophrenia, 45:239

bloodflow, temporal lobe, 45:239

catatonic syndrome, blood flow, 45:239

catatonic syndrome, schizophrenia, 45:239

catatonic syndrome, temporal lobe, 45:239

computed tomography, frontal lobe, 45:239

computed tomography, schizophrenia, 45:209

computed tomography, ventricular size, 45:209

frontal lobe, computed tomography, 45:209

frontal lobe, obsessive-compulsive disorder, 45:143

frontal lobe, schizophrenia, 45:209

frontal lobe, Tourette's syndrome, 45:143

frontal lobe, ventricular size, 45:209

iomazenil, benzodiazepine receptor ligand, 45:67

iomazenil, normal controls, 45:67

iomazenil, occipital lobes, 45:67

SPECT continued

ketanserin, affective disorder, 45:227

ketanserin, serotonin₂ receptor, 45:227

normal controls, benzodiazepine receptor ligand, 45:67

normal controls, iomazenil, 45:67

normal controls, occipital lobes, 45:67

obsessive-compulsive disorder, frontal lobe, 45:143

obsessive-compulsive disorder, Tourette's syndrome, 45:143

occipital lobes, benzodiazepine receptor ligand, 45:67

occipital lobes, iomazenil, 45:67

occipital lobes, normal controls, 45:67

schizophrenia, bloodflow, 45:239

schizophrenia, catatonic syndrome, 45:239

schizophrenia, computed tomography, 45:209

schizophrenia, frontal lobe, 45:209

schizophrenia, temporal lobe, 45:239

schizophrenia, ventricular size, 45:209

serotonin₂ receptor, affective disorder, 45:227

serotonin₂ receptor, ketanserin, 45:227

temporal lobe, bloodflow, 45:239

temporal lobe, catatonic syndrome, 45:239

temporal lobe, schizophrenia, 45:239

Tourette's syndrome, frontal lobe, 45:143

Tourette's syndrome, obsessive-compulsive disorder, 45:143

ventricular size, computed tomography, 45:209

ventricular size, frontal lobe, 45:209

ventricular size, schizophrenia, 45:209

xenon-133 vs. xenon-127, blood flow, 45:187

Substance abuse (see also **Alcoholism**)

cocaine, MRI, 45:15

heroin, MRI, 45:15

MRI, cocaine, 45:15

MRI, heroin, 45:15

Temporal lobe

blood flow, catatonic syndrome, 45:239

blood flow, schizophrenia, 45:239

blood flow, SPECT, 45:239

catatonic syndrome, blood flow, 45:239

catatonic syndrome, schizophrenia, 45:239

catatonic syndrome, SPECT, 45:239

schizophrenia, blood flow, 45:239

schizophrenia, catatonic syndrome, 45:239

schizophrenia, SPECT, 45:239

SPECT, blood flow, 45:239

SPECT, catatonic syndrome, 45:239

SPECT, schizophrenia, 45:239

Thalamus

dopamine, Huntington's disease, 45:203

dopamine, neuroleptics, 45:203

Thalamus continued

- dopamine, post-mortem study, 45:203
- dopamine, schizophrenia, 45:203
- Huntington's disease, dopamine, 45:203
- Huntington's disease, neuroleptics, 45:203
- Huntington's disease, post-mortem study, 45:203
- Huntington's disease, schizophrenia, 45:203
- neuroleptics, dopamine, 45:203
- neuroleptics, Huntington's disease, 45:203
- neuroleptics, post-mortem study, 45:203
- neuroleptics, schizophrenia, 45:203
- post-mortem study, dopamine, 45:203
- post-mortem study, Huntington's disease, 45:203
- post-mortem study, neuroleptics, 45:203
- post-mortem study, schizophrenia, 45:203
- schizophrenia, dopamine, 45:203
- schizophrenia, Huntington's disease, 45:203
- schizophrenia, neuroleptics, 45:203
- schizophrenia, post-mortem study, 45:203
- Topographic mapping**
- alcoholism, electroencephalography, 45:25
- artifact elimination, electroencephalography, 45:79
- caffeine, electroencephalography, 45:105
- caffeine, panic disorder, 45:105
- electroencephalography, alcoholism, 45:25
- electroencephalography, artifact elimination, 45:79
- electroencephalography, caffeine, 45:105
- electroencephalography, panic disorder, 45:105
- panic disorder, caffeine, 45:105
- panic disorder, electroencephalography, 45:105

Tourette's syndrome

- frontal lobe, obsessive-compulsive disorder, 45:143
- frontal lobe, SPECT, 45:143
- obsessive-compulsive disorder, frontal lobe, 45:143
- obsessive-compulsive disorder, SPECT, 45:143
- SPECT, frontal lobe, 45:143
- SPECT, obsessive-compulsive disorder, 45:143
- Trifluoperazine**
- fluoxetine, MR spectroscopy, 45:95
- fluoxetine, schizophrenia, 45:95
- MR spectroscopy, fluoxetine, 45:95
- MR spectroscopy, schizophrenia, 45:95
- schizophrenia, fluoxetine, 45:95
- schizophrenia, MR spectroscopy, 45:95
- Ventricular size**
- computed tomography, frontal lobe, 45:209
- computed tomography, schizophrenia, 45:209
- computed tomography, SPECT, 45:209
- frontal lobe, computed tomography, 45:209
- frontal lobe, schizophrenia, 45:209
- frontal lobe, SPECT, 45:209
- schizophrenia, computed tomography, 45:209
- schizophrenia, frontal lobe, 45:209
- schizophrenia, SPECT, 45:209
- SPECT, computed tomography, 45:209
- SPECT, frontal lobe, 45:209
- SPECT, schizophrenia, 45:209
- Xenon-133 vs. xenon-127**
- blood flow, SPECT, 45:187
- resolution, SPECT
- SPECT, blood flow, 45:187